Every S-1 that GT Biopharma Inc. (GTBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow GTBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GTBP filings page.
GT Biopharma, Inc. is registering up to 13,502,835 shares of common stock for resale by selling stockholders. The shares include common stock issuable upon conversion of Series M and Series L preferred stock, upon warrant exercise, and shares issued as preferred-stock dividends. The company will not receive proceeds from selling-stockholder sales, but may receive proceeds from cash warrant exercises or purchases under Series M or Series L Greenshoe Rights.
GT Biopharma reported 2,061,052 shares of common stock outstanding as of October 9, 2026, and $9,706,500 in gross proceeds before expenses from Series L Greenshoe Rights exercised to date, intended for working capital and general corporate purposes. The company states that substantial doubt has been raised about its ability to continue as a going concern and that additional financing on acceptable terms is not assured.
GT Biopharma, Inc. is registering up to 9,723,057 shares of common stock for resale by existing investors. The shares come from convertible Series L preferred stock, vested warrants, a stock dividend, and pre-funded advisory warrants.
The company will not receive proceeds from these resales, though it may receive cash if investors exercise vested warrants at $0.454 per share. GT Biopharma is a clinical-stage immuno-oncology company developing NK cell–engaging TriKE and Dual Targeting TriKE therapies and currently has 35,622,375 shares outstanding. Its Nasdaq-listed stock last closed at $0.27, and the company discloses a going concern risk and a Nasdaq minimum bid price deficiency.
GT Biopharma, Inc. is registering 22,686,349 shares of common stock for resale by existing investors. The shares include 11,257,949 shares issuable upon conversion of Series L 10% Convertible Preferred Stock, 11,257,949 shares issuable upon exercise of vested warrants from a May 2025 private placement, and 170,451 shares issued as a stock dividend on the Series L preferred. The company will not receive proceeds from resale of these shares, but may receive cash if investors exercise the vested warrants, which currently carry a $0.5319 exercise price.
GT Biopharma is a clinical-stage immuno-oncology company developing TriKE and Dual Targeting TriKE natural killer cell engagers. It reports substantial doubt about its ability to continue as a going concern without additional financing and notes a Nasdaq notice for failing to meet the $1.00 minimum bid price, with a compliance period through May 19, 2026. As of January 12, 2026, 26,652,194 common shares were outstanding and warrants to purchase 50,166,927 additional shares were outstanding, adding significant potential dilution if exercised.